Abstract |
The ventilatory effects of doxapram in the initial pharmacotherapy for apnea in the newborn were evaluated in 8 premature infants with idiopathic apnea. All received doxapram for 48 h at 0.25 mg/kg/h on the first day and 1 mg/kg/h on the second day. The ventilatory effects and the airway occlusion pressure (p0.1) were measured by means of a face mask, and a pneumotachograph. Compared to the pretreatment period, the mean of the frequency of central apnea greater than or equal to 15 s decreased significantly (p less than 0.01) by 48 and 75% during the first and second day, respectively. Both doses significantly increased inspiratory drive measured by airway occlusion pressure by 20% (p less than 0.05) and 32% (p less than 0.01) on the first and second day of drug treatment, respectively. Minute ventilation, tidal volume and mean respiratory flow significantly increased only with 1 mg/kg/h of doxapram, accompanied by a significant decrease in transcutaneous PCO2. No side effects were noted. Data suggested that doxapram alone at a dose of 1 mg/kg/h is effective for the treatment of neonatal apnea.
|
Authors | A Bairam, M Faulon, P Monin, P Vert |
Journal | Biology of the neonate
(Biol Neonate)
Vol. 61
Issue 4
Pg. 209-13
( 1992)
ISSN: 0006-3126 [Print] Switzerland |
PMID | 1610948
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Apnea
(drug therapy)
- Doxapram
(administration & dosage, therapeutic use)
- Female
- Humans
- Infant, Newborn
- Infant, Premature, Diseases
(drug therapy)
- Male
- Respiration
(physiology)
- Total Lung Capacity
|